Undisclosed Radiotheranostic Programs
Oncology
Pre-clinicalActive
Key Facts
About Lumiphore
Lumiphore is a private, pre-clinical stage biotech firm leveraging its novel chelation platform to advance the field of radiotheranostics and diagnostics. Its core technology enables rapid, room-temperature labeling of a wide range of therapeutic and diagnostic radioisotopes, such as Lutetium and Zirconium, to targeting agents with high stability. The company is pursuing internal programs and partnerships to develop next-generation radiopharmaceuticals while also commercializing its lanthanide compounds for sensitive diagnostic assays. Lumiphore operates as an enabling technology provider, seeking collaborations with companies possessing novel targeting molecules.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |